iptacopan (LNP023)

iptacopan · Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for iptacopan (LNP023), covering 2023-11-15 to 2026-04-01. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy [Phase 3]

See pricing